Galera Therapeutics (NASDAQ:GRTX) and ObsEva (NASDAQ:OBSV) Financial Comparison

Volatility & Risk

Galera Therapeutics has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Earnings and Valuation

This table compares Galera Therapeutics and ObsEva”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08 million	$0.64	0.16
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A

ObsEva is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Galera Therapeutics and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
ObsEva	N/A	-416.36%	-92.01%

About Galera Therapeutics

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.